A prospective, randomized, open-label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with tacrolimus-associated abnormal glucose metabolism to cyclosporine micro-emulsion with C2 monitoring

Trial Profile

A prospective, randomized, open-label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with tacrolimus-associated abnormal glucose metabolism to cyclosporine micro-emulsion with C2 monitoring

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2011

At a glance

  • Drugs Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection; Renal transplant rejection
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top